Preparation method of zalvizepam intermediate

The synthesis process of Zavejipan intermediates is simplified through enzyme catalytic methods, solving the cumbersome and cost-effective problems in the existing technology, and achieving efficient and environmentally friendly intermediate production, which is suitable for industrial applications.

CN119059977APending Publication Date: 2024-12-03PORTON PHARMA SOLUTIONS LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310630899.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-03

Smart Images

  • Figure CN119059977A_ABST
    Figure CN119059977A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of (R)-2-amino-3-(7-methyl-1H-indazole-5-yl) methyl propionate, a compound of a formula V is subjected to enzyme catalysis to prepare a compound of a formula VI, the compound of the formula VI is esterified to obtain the (R)-2-amino-3-(7-methyl-1H-indazole-5-yl) methyl propionate, and the method solves the problems of complexity and high cost in the prior art. According to the method, enzyme catalysis is adopted, green production is achieved, the yield is increased, and operation is easy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of pharmaceutical engineering, and in particular to a preparation method of zavirigopam. Background Art

[0002] (R)-2-amino-3-(7-methyl-1H-indazol-5-yl) propionic acid methyl ester and its corresponding salts are key intermediates in the synthesis of zavidipam. It is used for the acute treatment of migraine with or without aura in adults and is not suitable for the preventive treatment of migraine. The drug is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray.

[0003]

[0004] There are few reported synthesis methods for this intermediate, mainly the following two methods:

[0005] 1. Constructing a chiral center with a chiral catalyst (US20060122250, US20070049577, WO2011123232A1, WO2020249969A1, WO2021127070A1): Prepare an enamine intermediate and construct a chiral center by asymmetric reduction under a rhodium or palladium catalyst. This method has a long synthesis step and the catalyst used is very expensive, and the feasibility of industrial scale-up is low.

[0006] 2. Using keto acid as an intermediate, the chiral center is constructed through enzyme catalysis (Org. Process Res. Dev. 2012, 16, 1953-1966, Org. Process Res. Dev. 2008, 12, 1119–1129): This method has a long route, the yield is not advantageous, and the post-processing is relatively cumbersome.

[0007] In order to solve the above-mentioned problems, a new method for preparing methyl (R)-2-amino-3-(7-methyl-1H-indazol-5-yl)propanoate is needed. Summary of the invention

[0008] In view of the deficiencies in the prior art, the present invention provides a method for preparing methyl (R)-2-amino-3-(7-methyl-1H-indazol-5-yl) propionate, which solves the problems of complicatedness and high cost of the prior art. The present invention uses enzyme catalysis, realizes green production, improves yield and is simple to operate.

[0009] To achieve the above object, the present invention adopts the following technical solutions:

[0010] The first technical solution of the present invention discloses a compound of formula IV

[0011]

[0012] The second technical solution of the present invention discloses a method for preparing a zavidigpan intermediate, comprising the following steps:

[0013] The compound of formula V is prepared by enzyme catalysis to obtain the compound of formula VI, and the compound of formula VI is esterified to obtain (R)-2-amino-3-(7-methyl-1H-indazol-5-yl) propionic acid methyl ester or its salt,

[0014]

[0015] Among them, the enzyme is sequence Seq NO:1.

[0016] Furthermore, the enzyme-catalyzed reaction conditions are as follows: adjusting the pH to 8-10 and the reaction temperature to 20-30°C.

[0017] Furthermore, the temperature of enzyme catalysis is to adjust the pH to 9-10 and the reaction temperature to 22-28°C.

[0018] Furthermore, the mass ratio of the compound of formula V to the enzyme is 5:1-3.

[0019] The third technical solution of the present invention discloses a method for preparing a compound of formula V, comprising the following steps:

[0020]

[0021] Furthermore, the molar ratio of the compound of formula III to the compound of formula IV is 1:1 to 1.3.

[0022] Furthermore, the reaction condition is that morpholine is also added, and the molar ratio of morpholine to the compound of formula III is 1:5-6.

[0023] The fourth technical solution of the present invention discloses another method for preparing the compound of formula V, comprising the following steps:

[0024]

[0025] The compound of formula I reacts with a nitrous acid reagent to obtain a compound of formula II, and the compound of formula II reacts with dimethyl sulfoxide to obtain a compound of formula III.

[0026] Furthermore, the molar ratio of the compound of formula I to the nitrous acid reagent is 1:1-1.7; the molar ratio of the compound of formula II to dimethyl sulfoxide is 1:4-5.

[0027] Compared with the prior art, the present invention has the following beneficial effects:

[0028] The present invention discloses a new compound formula V, and a new synthetic route is obtained through the new compound. The formula V compound of the present invention is easy to prepare, and the formula V compound is catalyzed by phenylalanine enzyme to obtain a high-yield formula VI compound, and the formula VI compound is esterified to obtain a final product. The present invention avoids the use of expensive metal catalysts and ligands, and the route is shorter. The enzyme catalysis of the formula V compound increases the yield of the final product, reduces the production cost, and the product selectivity after enzyme catalysis is good, the operation is safe, and it is more suitable for large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 Example 1 Hydrogen spectrum of the compound of formula II;

[0030] Figure 2 Example 2 Hydrogen spectrum of the compound of formula III;

[0031] Figure 3 Example 3-1 Hydrogen spectrum of the compound of formula V;

[0032] Figure 4 Example 3-1 High performance liquid chromatogram of the compound of formula V;

[0033] Figure 5 LCMS spectrum of the compound of formula VI of Example 4-1;

[0034] Figure 6 High performance liquid chromatograms of the compound of formula VI and standard enantiomers of the compound of formula VI;

[0035] Figure 7 Example 4-1 High performance liquid chromatogram of compound of formula VI

[0036] Figure 8 LCMS spectrum of the intermediate (R)-2-amino-3-(7-methyl-1H-indazol-5-yl)propanoic acid methyl ester of Example 5; DETAILED DESCRIPTION

[0037] The present invention is further described in detail below, and specific implementation methods are given.

[0038] The route disclosed by the present invention is as follows:

[0039]

[0040] The compound of formula I reacts with a nitrous acid reagent to obtain a compound of formula II, and the compound of formula II reacts with dimethyl sulfoxide to obtain a compound of formula III. The molar ratio of the compound of formula I to the nitrous acid reagent is 1:1-1.7; the molar ratio of the compound of formula II to dimethyl sulfoxide is 1:4-5. The molar ratio of the compound of formula I to the nitrous acid reagent is 1:1.0, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7. The molar ratio of the compound of formula II to dimethyl sulfoxide is 1:4.0, 1:4.1, 1:4.2, 1:4.3, 1:4.4, 1:4.5, 1:4.6, 1:4.7, 1:4.8, 1:4.9, 1:5.0.

[0041] Nitrous acid reagents include tert-butyl nitrite.

[0042] The compound of formula III reacts with the compound of formula IV to prepare the compound of formula V, the molar ratio of the compound of formula III to the compound of formula IV is 1:1.0-1.4, and the reaction condition is that morpholine is also added, and the molar ratio of morpholine to the compound of formula III is 1:5-6.

[0043] Preferably, the molar ratio of the compound of formula III to the compound of formula IV is 1:1.0, 1:1.1, 1:1.2, 1:1.3, 1:1.4;

[0044] The molar ratio of morpholine to the compound of formula III is 1:5.0, 1:5.1, 1:5.2, 1:5.3, 1:5.4, 1:5.5, 1:5.6, 1:5.7, 1:5.8, 1:5.9, and 1:6.0.

[0045] Preferably, the reaction temperature of the compound of formula III and the compound of formula IV is 100-120°C, and the reaction time of the compound of formula III and the compound of formula IV is 5-30 hours. Further, the reaction temperature is 100°C, 101°C, 102°C, 103°C, 104°C, 105°C, 106°C, 107°C, 108°C, 109°C, 110°C, 111°C, 112°C, 113°C, 114°C, 115°C, 116°C, 117°C, 118°C, 119°C, 120°C.

[0046] The compound of formula V is prepared by enzyme catalysis to obtain the compound of formula VI, and the compound of formula VI is esterified to obtain (R)-2-amino-3-(7-methyl-1H-indazol-5-yl)propionic acid methyl ester, wherein the amino acid sequence of the enzyme is Seq NO: 1, and the enzyme is phenylalanase.

[0047] .

[0048] Furthermore, the enzyme-catalyzed reaction conditions are as follows: adjusting the pH to 8.0-10.0 and the reaction temperature to 20-30°C.

[0049] Furthermore, the temperature of enzyme catalysis is to adjust the pH to 9.0-10.0 and the reaction temperature to 22-28°C. The pH is 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0. The reaction temperature is 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C.

[0050] Further, the mass ratio of the compound of formula V to the enzyme is 5:1 to 3. Preferably, the mass ratio of the compound of formula V to the enzyme is 5:1.5 to 2.5. The mass ratio of the compound of formula V to the enzyme is 5:1.5, 5:1.6, 5:1.7, 5:1.8, 5:1.9, 5:2.0, 5:2.1, 5:2.2, 5:2.3, 5:2.4, 5:2.5.

[0051] The method also includes a post-treatment step. After the reaction is completed, an acid is used to adjust the pH to 1-2, the reaction solution after the pH is adjusted is placed in a centrifuge with a rotation speed of 10000-14000, the supernatant is collected, MTBE is added for extraction, the water layer is collected, 10% sodium hydroxide aqueous solution is added to the aqueous phase to adjust the pH to 10-11, and the solution is concentrated to dryness to obtain a white solid.

[0052] Preparation of enzyme powder: Send the coding gene of the enzyme amino acid sequence SEQ ID NO: 1 to the supplier company for codon optimization and full gene synthesis, and connect it into the plasmid; transfer the recombinant plasmid into the engineered bacteria, and culture the bacterial solution; pick the transformant for sequencing verification.

[0053] The recombinant bacteria are inoculated into a culture medium, cultured, induced, and centrifuged to collect the bacteria, added with PBS buffer and resuspended, and after resuspending, the cells are ultrasonically disrupted, and the solution is freeze-dried to obtain phenylalanase powder.

[0054] Example 1

[0055] Synthesis of 5-Bromo-7-methyl-1H-indazole

[0056]

[0057] Add the compound of formula I 4-bromo-2,6-dimethylaniline (150.0 g) and toluene (2.0 L) to the three-necked flask, stir and dissolve to clarify, add potassium acetate (112.0 g), control the internal temperature to be less than 40 ° C, add glacial acetic acid (64.5 g) dropwise, control the internal temperature to be less than 50 ° C, add tert-butyl nitrite (99.0 g) dropwise, and keep the internal temperature at 40 ° C-50 ° C for 5 hours. TLC confirms that the raw material reaction is complete. Turn off the heating, cool to room temperature, add ethyl acetate (500 mL), and add sodium hydroxide to adjust the pH to 9-10. Separate the liquid, collect the organic phase, add ethyl acetate (400 mL) to the aqueous phase, combine the organic phases, concentrate under reduced pressure to a volume of 1.5v, add n-heptane (800 mL) for slurrying for 5 hours, filter, and dry to obtain 131.1 g of yellow solid, yield: 82.8%, purity 98.53%. 1H NMR (400MHz, CDCl3) δ8.04 (s, 1H), 7.75 (d, J = 0.88Hz, 1H), 7.28 (d, J = 0.88Hz, 1H), 2.56 (s, 3H), such as Figure 1 shown.

[0058] Example 2

[0059] Synthesis of 7-Methyl-5-aldehyde-1H-indazole

[0060]

[0061] Add the compound of formula II (22.0 g) to a three-necked flask, add anhydrous tetrahydrofuran (330 mL), stir to dissolve and clarify, and replace with nitrogen three times. The reaction solution is cooled to -60°C, n-butyl lithium (2.5M n-hexane solution, 62.5 mL) is added dropwise, and after the dropwise addition is completed, sec-butyl lithium (1.3M n-hexane solution, 200 mL) is added after the dropwise addition is completed and stirred for 1 hour, and DMF (32.5 mL) is added after the dropwise addition is completed and continued to stir for 1 hour. The reaction solution is slowly heated to room temperature, and water (220 mL) is added dropwise to quench the reaction, and the internal temperature is controlled to be ≤25°C. Dichloromethane (200 mL*3) was added for extraction, the organic phases were combined, and concentrated to dryness under reduced pressure. Ethyl acetate (50 mL) was added for dilution, and cyclohexane (250 mL) was slowly added. After stirring for 1 h, the temperature was lowered to 0-10°C, and stirring was continued for 2 h. The filter cake was filtered with suction, and cyclohexane (50 mL) was added to wash the filter cake. The filter cake was dried to obtain 13.6 g of gray solid with a yield of 81.4% and a purity of 91.5%. 1 H NMR (400MHz, CDCl3) δ13.75(brs,1H),9.97(s,1H),8.32(s,1H),8.25(d,J=0.64,1H),7.60(d,J=0.64Hz,1H),2.57(s,3H), such as Figure 2 shown.

[0062] Example 3

[0063] Synthesis of (E)-3-(7-methyl-1H-indazol-5-yl)acrylic acid

[0064]

[0065] Example 3-1

[0066] In a single-mouth bottle, add the compound of formula III (6.00g) and toluene (66ml) in sequence, add the compound of formula IV malonic acid (5.10g) and morpholine (0.60g) under stirring at room temperature, after addition, slowly heat the reaction solution to 110°C and reflux, react for 16h. After TLC detection of the complete reaction of the raw material, cool and concentrate to dryness, add anhydrous ethanol (20mL) to the crude product, reflux and beat for 3h, then cool to room temperature, filter, and add ethanol (5mL) for washing. Dry at 50°C to obtain a yellow solid 5, yield: 82.1%, purity 97.58%. 1 H NMR(400MHz,DMSO-d6)δ13.33(brs,1H),12.23(brs,1H),8.11(s,1H),7.85(s,1 H),7.67(dd,J=16.0Hz,1H),7.55(s,1H),6.46(dd,J=16.0Hz,1H),2.50(s,1H), such as Figure 3 , 4 shown.

[0067] Example 3-2

[0068] In a single-mouth bottle, add the compound of formula III (6.4g, 0.040mol) and toluene (74ml) in sequence, add the compound of formula IV malonic acid (5.8g, 0.056mol) and morpholine (0.058g, 0.007mol) under stirring at room temperature, after addition, slowly heat the reaction solution to 100℃ and reflux, react for 10h. After TLC detection, the raw material reacts completely, cool and concentrate to dryness, add anhydrous ethanol (20mL) to the crude product, reflux and beat for 3h, then cool to room temperature, filter, and add ethanol (5mL) for washing. Dry at 50℃ to obtain a yellow solid 5, with a yield of 80.1% and a purity of 95.8%.

[0069] Example 3-3

[0070] In a single-mouth bottle, add the compound of formula III (7.20g, 0.045mol) and toluene (59ml) in sequence, add the compound of formula IV malonic acid (4.68g, 0.045mol) and morpholine (0.78g, 0.009mol) under stirring at room temperature, after addition, slowly heat the reaction solution to 120℃ and reflux, react for 15h. After TLC detection, the raw material reacts completely, cool and concentrate to dryness, add anhydrous ethanol (20mL) to the crude product, reflux and beat for 3h, then cool to room temperature, filter, and add ethanol (5mL) for washing. Dry at 50℃ to obtain a yellow solid 5, with a yield of 79.1% and a purity of 95.3%.

[0071] Embodiment 3-4

[0072] In a single-mouth bottle, add the compound of formula III (5.60g, 0.035mol) and toluene (51ml) in sequence, add the compound of formula IV malonic acid (4.37g, 0.042mol) and morpholine (0.55g, 0.006mol) under stirring at room temperature, after addition, slowly heat the reaction solution to 115℃ and reflux, react for 18h. After TLC detection, the raw material reacts completely, cool and concentrate to dryness, add anhydrous ethanol (20mL) to the crude product, reflux and slurry for 3h, then cool to room temperature, filter, and add ethanol (5mL) for washing. Dry at 50℃ to obtain a yellow solid 5, with a yield of 81.7% and a purity of 97.2%.

[0073] Example 4

[0074] Synthesis of (R)-2-amino-3-(7-methyl-1H-indazol-5-yl)propionic acid

[0075]

[0076] Example 4-1

[0077] Add the compound of formula V (500 mg) to a 100 mL single-mouth bottle, add an aqueous ammonia solution (50 mL) adjusted to pH 9.6 with acetic acid, add enzyme powder (200 mg), and react at 25°C for 24 hours. After the reaction is completed, add concentrated hydrochloric acid to adjust the pH to 1-2. Place the reaction solution after pH adjustment in a centrifuge at 12,000 rpm for 5 minutes, collect the supernatant, add MTBE extraction (50 mL*3), collect the water layer, add 10% sodium hydroxide aqueous solution to the aqueous phase to adjust the pH to 10-11, and concentrate to dryness to obtain a white solid; the yield is 91%, the HPLC purity is 95.5%, and the optical purity is 93.41%. Figure 5 , 6 , 7 shown in Example 4-2

[0078] To a 100 mL single-mouth bottle, add the compound of formula V (500 mg), add an aqueous ammonia solution (50 mL) adjusted to pH 9.5 with acetic acid, add enzyme powder (150 mg), and react at 22° C. for 24 h. After the reaction is completed, add concentrated hydrochloric acid to adjust the pH to 1-2. The reaction solution after pH adjustment is placed in a centrifuge at 10,000 rpm for 5 minutes, collect the supernatant, add MTBE extraction (50 mL*3), collect the water layer, add 10% sodium hydroxide aqueous solution to the aqueous phase to adjust the pH to 10-11, and concentrate to dryness to obtain a white solid; the yield is 90%, the HPLC purity is 95.3%, and the optical purity is 93.40%.

[0079] Example 4-3

[0080] To a 100 mL single-mouth bottle, add the compound of formula V (500 mg), add an aqueous ammonia solution (50 mL) adjusted to pH 9.0 with acetic acid, add enzyme powder (160 mg), and react at 28°C for 24 h. After the reaction is completed, add concentrated hydrochloric acid to adjust the pH to 1-2. The reaction solution after pH adjustment is placed in a centrifuge at 12,000 rpm for 5 minutes, collect the supernatant, add MTBE extraction (50 mL*3), collect the water layer, add 10% sodium hydroxide aqueous solution to the aqueous phase to adjust the pH to 10-11, and concentrate to dryness to obtain a white solid; the yield is 90%, the HPLC purity is 95.0%, and the optical purity is 93.41%.

[0081] Example 4-4

[0082] To a 100 mL single-mouth bottle, add the compound of formula V (500 mg), add an aqueous ammonia solution (50 mL) adjusted to pH 10.0 with acetic acid, add enzyme powder (250 mg), and react at 25° C. for 24 h. After the reaction is completed, add concentrated hydrochloric acid to adjust the pH to 1-2. The reaction solution after pH adjustment is placed in a centrifuge at 14,000 rpm for 5 minutes, collect the supernatant, add MTBE extraction (50 mL*3), collect the water layer, add 10% sodium hydroxide aqueous solution to the aqueous phase to adjust the pH to 10-11, and concentrate to dryness to obtain a white solid; the yield is 91%, the HPLC purity is 95.2%, and the optical purity is 93.35%.

[0083] Example 5

[0084] Synthesis of Methyl (R)-2-Amino-3-(7-methyl-1H-indazol-5-yl) Propionate

[0085]

[0086] Add the compound of formula VI (200 mg) to a single-mouth bottle, add methanol (2 mL), add acetyl chloride (143 mg), and after the addition, heat to 60°C for 16 hours. TLC detection shows that the raw material is completely converted. The reaction solution is concentrated under reduced pressure to obtain a light yellow solid with a yield of 99.1% and a purity of 91.93%. LCMS (ESI) m / z = 234.1 [M+H] + ,like Figure 8 shown.

[0087] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.

Claims

1. A compound of formula IV 2. A method for preparing a zawigipan intermediate, It is characterized in that The following steps are involved: The compound of formula V is prepared by enzyme catalysis to obtain the compound of formula VI, and the compound of formula VI is esterified to obtain (R)-2-amino-3-(7-methyl-1H-indazol-5-yl) propionic acid methyl ester or its salt, Among them, the enzyme is sequence Seq NO:

1.

3. The preparation method according to claim 2, It is characterized in that The reaction conditions for enzyme catalysis are: adjusting the pH to 8-10 and the reaction temperature to 20-30°C.

4. The preparation method according to claim 3, It is characterized in that The temperature for enzyme catalysis is to adjust the pH to 9-10 and the reaction temperature to 22-28°C.

5. The preparation method according to claim 4, It is characterized in that The mass ratio of the compound of formula V to the enzyme is 5:1-3.

6. A method for preparing a compound of formula V, It is characterized in that The following steps are involved:

7. The method according to claim 6, It is characterized in that The molar ratio of the compound of formula III to the compound of formula IV is 1:1.0-1.

3.

8. The method according to claim 7, It is characterized in that The reaction conditions are as follows: morpholine is also added, and the molar ratio of morpholine to the compound of formula III is 1:5.0-6.

0.

9. A method for preparing a compound of formula V, It is characterized in that The following steps are involved: The compound of formula I reacts with a nitrous acid reagent to obtain a compound of formula II, and the compound of formula II reacts with dimethyl sulfoxide to obtain a compound of formula III.

10. The preparation method according to claim 9, It is characterized in that The molar ratio of the compound of formula I to the nitrous acid reagent is 1:1.0-1.7; The molar ratio of the compound of formula II to dimethyl sulfoxide is 1:4.0-5.0.

Citation Information

Cited By

  • Synthesis method of zavigepam chiral intermediate

    CN121698810A